Xinjiang Bai Hua Cun Pharma Tech Co.,Ltd. (600721.SH) issued a statement on August 12, revealing that its stock price has experienced an unusual surge, with cumulative closing price gains exceeding 100% over a 10-trading-day period. This qualifies as a case of severe abnormal share price fluctuation under the relevant rules of the Shanghai Stock Exchange.

The company emphasized that it is primarily a CRO (Contract Research Organization) focused on the development of small-molecule generic chemical drugs and is not involved in the research and development of innovative drugs. In the first quarter of 2026, the company recorded operating revenue of 67.1829 million yuan, a year-on-year decrease of 30.68%, while net profit attributable to shareholders of the listed company was 6.6427 million yuan, a decline of 67.94% year-on-year.

Currently, the company's core business has not undergone any significant changes. The market environment and industry policies have not seen major adjustments. The recent continuous rise in the stock price, however, has sharply deviated from the company's actual operational performance, the statement noted.